ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL3322 |
|
330829-30-6 |
MRT-10 (MRT 10) 98+% |
C24H23N3O5S | |
CL3321 |
|
306387-90-6 |
KAAD-Cyclopamine (Synonyms: Cyclopamine-KAAD;3-Keto-N-aminoethyl-N’-aminocaproyldihydrocinnamoyl Cyclopamine) 98+% |
C44H63N3O4 | |
CL3073 |
|
2996821-30-6 |
LM-41 98+% |
C19H14FNO2 | |
CL2397 |
|
127243-85-0 |
H-89 98+% |
C20 H20 Br N3 O2 S | |
CL2889 |
|
667463-62-9 |
BIO (GSK-3 Inhibitor IX | 6-bromoindirubin-3-oxime | 6-Bromoindirubin-3'-oxime | MLS 2052 | (2'Z,3'E)-6-Bromoindirubin-3'-oxime | 6-BIO | 6BIO 99+% |
C16 H10BrN3O2 | |
CL2888A |
|
905854-03-7 |
(3S,4S)-Tivantinib | 3S,4S)-ARQ 197 | ARQ 198 98+% |
C23H19N3O2 | |
CL1006C |
|
2109414-84-6 |
Laduviglusib dihydrochloride | CHIR-99021 dihydrochloride | CT99021 dihydrochloride 98+% |
C22H18Cl2N8·2HCl | |
CL2733A |
|
2109704-99-4 |
Belumosudil mesylate (KD025 mesylate; SLx-2119 mesylate) 98+% |
C27H28N6O5S | |
CL2709 |
|
1422144-42-0 |
Netarsudil dimesylate ( AR-13324 dimesylate) 98+% |
C30H35N3O9S2 | |
CL2506 |
|
40391-99-9 |
Pamidronic Acid 98+% |
C3H11NO7P2 | |
CL2425 |
|
425386-60-3 |
Semagacestat | LY450139 98+% |
C19H27N3O4 | |
CLA1355 |
|
1447814-75-6 |
Brontictuzumab (Anti-NOTCH1) 95+% |
— | |
CLA1337 |
|
1345009-45-1 |
Vantictumab (Anti-FZD) 95+% |
— | |
CLA1334 |
|
1359940-55-8 |
Tarextumab (Anti-NOTCH3) 95+% |
— | |
CLA1299 |
|
1243262-17-0 |
Demcizumab (Anti-DLL4) 95+% |
— | |
CL2221 |
|
1226056-71-8 |
Thiazovivin 98+% |
C15H13N5OS | |
CL2213 |
|
686770-61-6 |
N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2- d ]pyrimidin-2-yl)thio]-acetamide; IWP-2 98+% |
C22H18N4O2S3 | |
CL1172 |
|
331752-47-7 |
Y27632 HCl hydrate | (R)-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide Dihydrochloride Monohydrate | Y-27632 Dihydrochloride Monohydrate 98+% |
C14H25Cl2N3O2 | |
CL1621 |
|
865854-05-3 |
Tideglusib (Synonyms: NP031112; NP-12) 98+% |
C19H14N2O2S | |
CL1037 |
|
879085-55-9 |
Vismodegib (GDC-0449) 98+% |
C19H14Cl2N2O3S | |